# Rigen Biotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/rigen-biotech

- Industry: Medical Devices & Equipment
- Headquarters: Shanghai, China
- Website: www.rigen-bio.com
- Total disclosed funding: $45M
- Latest round: Series B (May 16, 2025)
- Investors on record: 8

## About

Based in Shanghai, China and founded in 2017, Shanghai Rigen Biotechnology Co., Ltd., doing business as Rigen Biotech, is a high-technology company that focuses on the development, production, sales and testing services of individual molecular diagnosis products. The company has an international standard GMP plant and R&D laboratory covering an area of 2,500 square meters and has established a sound ISO13485 quality management system. In addition, the company has 7 domestic invention patents and 15 software copyrights. The company established a QPCR R&D laboratory in December 2017 and an NGS R&D laboratory in January 2018. Rigen Biotech received a Class I medical device product filing and a Class I medical device manufacturing filing in 2019. 

In May 2025, Rigen Biotech raised approximately CNY 100.00 million in series B funding led by new investor Efung Capital, with participation from new investor Shanghai Fengxian Investment (Group).

Rigen Biotech provides three main lines of products, including medical consumables such as disposable thyroid biopsy needle products which are specifically designed for obtaining thyroid tissue specimens via percutaneous puncture; PCR (polymerase chain reaction) testing platforms such as real-time quantitative PCR and digital PCR testing devices which are used in fields such as pathogen determination, tumor gene detection and polymorphism research; and NGS (next-generation sequencing) DNA sequencing platforms which are applied in de novo sequencing assembly, transcriptome sequencing and methylation detection, etc. The company generates revenue from developing and sales of medical consumables and testing devices for thyroid disease and oncology sectors.

The series B financing will help Ruijing Biotech further accelerate its commercialization process, iterate its clinical product pipeline, advance the scientific discovery and proof-of-concept of cutting-edge products, improve its integrated layout for the diagnosis and treatment of thyroid diseases, and consolidate its position in the thyroid disease sector.

## Funding rounds

- Series B, May 16, 2025, $14M — Efung Capital, Shanghai Fengxian Investment (Group)
- Series B, Apr 14, 2022, $16M — GTJA Innovation Investment, BioTrack Capital, Rencent Capital
- Series A, Feb 22, 2021, $15M — Oriza Holdings, ZhenFund, Prosperico Ventures

## Investors

- Oriza Holdings (https://capitalatlas.ai/funds/oriza-holdings) — Series A
- ZhenFund (https://capitalatlas.ai/funds/zhenfund) — Series A
- Prosperico Ventures (https://capitalatlas.ai/funds/prosperico-ventures) — Series A
- GTJA Innovation Investment (https://capitalatlas.ai/funds/gtja-innovation-investment) — Series B
- BioTrack Capital (https://capitalatlas.ai/funds/biotrack-capital) — Series B
- Rencent Capital (https://capitalatlas.ai/funds/rencent-capital) — Series B
- Efung Capital (https://capitalatlas.ai/funds/efung-capital) — Series B
- Shanghai Fengxian Investment (Group) — Series B